Page 3 - Recursion Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

While relatively modest in size, the investment from Nvidia could help prove Recursion’s datasets give discovery platforms a speed-to-clinic edge.

"TechBio" company Recursion Pharma has entered agreements to acquire AI/ML company Cyclica for $40 million and Valence for $47.5 million.

/PRNewswire/ -- Targeted therapies specifically attach to and hinder cancer-causing proteins, but cancer cells can quickly evolve to thwart their action. A...

NEW YORK, Oct. 17, 2022 /PRNewswire/ -- Targeted therapies specifically attach to and hinder cancer-causing proteins, but cancer cells can quickly...

Prototype Shows Promise As Approach to Countering Pancreatic Cancer News provided by Share this article Share this article NEW YORK, May 11, 2021 /PRNewswire/ -- A research team has designed a molecule with potential to interfere in a new way with altered proteins that cause abnormal growth in 35 percent of pancreatic cancers. Published online in Nature Communications on May 11, a new study found that a molecule called a monobody clings to cancer-causing versions of the KRAS protein and keeps them from transmitting their signals. Changes in the DNA of the KRAS gene – which encodes a molec...